Protagonist Therapeutics and PPL report earnings updates

earnings forecasts biotech sector utility earnings capital investment stock market

Protagonist Therapeutics, Inc. saw a reduction in its Q3 2026 earnings per share estimates by HC Wainwright. Analyst D. Tsao lowered the forecast to $2.55 per share from a previous estimate of $2.88. Despite this reduction, the company maintains an average

Entities

Blackstone · HC Wainwright · PPL · Protagonist Therapeutics · Protagonist Therapeutics, Inc. · Prothena

Sources

Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results [www.marketbeat.com]

5 days ago

PPL Q2 Earnings Call Highlights [www.marketbeat.com]

5 days ago